TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02202356
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02554279
Drug: recombinant FSH
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01348009
Drug: Tesetaxel-capecitabine-cisplatin
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Phase 1: Tesetaxel orally on Day 1 of each cycle at dose of 18, 21, 24, or 27 mg/m2. If no dose-limiting toxicity, at least 3 subjects will be treated at each dose level until the maximum tolerated dose or the maximum dose of 27 mg/m2 is reached. At each tesetaxel dose level, capecitabine orally at a dose of 2000 mg/m2/day (administered in 2 equally divided doses) on Day 1-Day 14 and cisplatin intravenously at a dose of 60 mg/m2 on Day 1.~Phase 2: Tesetaxel orally on Day 1 of each cycle at dose determined in Phase 1. Capecitabine orally at a dose of 2000 mg/m2/day (administered in 2 equally divided doses) on Day 1-Day 14 and cisplatin intravenously at a dose of 60 mg/m2 on Day 1.
Study: NCT00291356
Drug: GSK189075 oral tablets
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00291356
Drug: GW869682 oral tablets
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02239120
Drug: optional ASA as comedication
Approvals — FDA: no, EMA: no, PMDA: no
Description: optional concomitant treatment which can be used for patients with coronary artery disease. It is not required for these pts.
Study: NCT02239120
Drug: placebo to ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo to comparator drug
Study: NCT02239120
Drug: placebo to optional ASA as comedication
Approvals — FDA: no, EMA: no, PMDA: no
Description: optional concomitant treatment which can be used for patients with coronary artery disease. It is not required for these pts.
Study: NCT01976988
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous Heparin 5000 Units given in the preoperative area one hour prior to surgery and continued every 8 hours for the remainder of the patients hospital course
Study: NCT02414568
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin 40 mg/m² IV
Study: NCT00500656
Drug: Oral Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: hard capsule matched to tranexamic acid
Study: NCT00500656
Drug: S.C. Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution for injection, matched to icatibant for injection
Study: NCT01119937
Drug: NVA237
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50µg capsules for inhalation, delivered via a single dose dry powder inhaler (Concept 1®)
Study: NCT03446144
Drug: Placebo (sterline saline 0.9%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calculated volume to match active comparator. Administered subcutaneously weekly for weeks 1-3, and every other week or less frequently until week 70
Study: NCT02224118
Drug: CNTO 3649 10 mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of 10 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
Study: NCT02224118
Drug: CNT0 3649 30 mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of 30 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men and multiple doses of 30 mcg/kg of CNTO 3649 will be administered to participants with type 2 diabetes mellitus as subcutaneous injections once weekly for 4 weeks.
Study: NCT02224118
Drug: CNTO 3649 100 mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of 100 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men and multiple doses of 100 mcg/kg of CNTO 3649 will be administered to participants with type 2 diabetes mellitus as subcutaneous injections once weekly for 4 weeks.
Study: NCT02224118
Drug: CNTO 3649 300 mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of 300 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
Study: NCT02224118
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo to CNTO 3649 will be administered to both healthy volunteers and participants with type 2 diabetes mellitus.
Study: NCT01986777
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo capsules will be filled with lactose.
Study: NCT03485495
Drug: Divaza
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration.
Study: NCT03485495
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration.
Study: NCT01323920
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate 15 mg/m\^2 IV
Study: NCT00081510
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02025621
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT04559529
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo pill will look just like the levetiracetam pill, but does not contain any levetiracetam.
Study: NCT03617003
Drug: WST11 mediated vascular targeted phototherapy (VTP)
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive intravenous administration of WST11 at a dose of 4 mg/kg, infused over 10 minutes while patients are under anesthesia during their endoscopy procedure, followed by immediate laser light application.
Study: NCT00689273
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be matched to PF-04136309. Dose, frequency, and duration same as PF-04136309.
Study: NCT00098982
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00098982
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00518960
Drug: ProAlgaZyme
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00881543
Drug: Dipeptidyl Peptidase IV inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage 100 mg each day, once a day, 2 months
Study: NCT00484185
Drug: BeneFIX (coagulation factor IX (recombinant))
Approvals — FDA: no, EMA: no, PMDA: no
Description: BeneFIX will be administered according to physician's discretion.
Study: NCT00494767
Drug: GW869682
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW869682 tablet with a dose strength of 250 mg will be available for subjects
Study: NCT00494767
Drug: GSK189075
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK189075 tablet with a dose strength of 250 mg will be available for subjects
Study: NCT00494767
Drug: GSK189075-Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets to match GSK189075 250 mg will be available for subjects
Study: NCT00494767
Drug: GW869682-Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets to match GW869682 250 mg will be available for subjects
Study: NCT03956368
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg (every evening orally) for 8 weeks.
Study: NCT01478360
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intravenous injection
Study: NCT00619905
Drug: ACZ885
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01909752
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (300 mg/m2) will be administered as a single dose three days prior to beginning vaccine therapy.
Study: NCT03836807
Drug: OKITASK®
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose of OKITASK® 40 mg was administered to patients within 3 hours after extraction of a molar tooth (VAS ≥ 30 mm). Each patient received one sachet that contained KLS 40 mg (equivalent to 25 mg of ketoprofen). The content of the entire sachet was placed on the patient's tongue and swallowed. A glass of water was immediately administered after the intake of the study drug in order to rinse mouth for all subjects.
Study: NCT02679339
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01101191
Drug: Reformulated OXY (oxycodone HCl)
Normalized name: Oxy Gard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reformulated OXY 80-mg tablet x 1 dose taken without food.
Study: NCT01101191
Drug: Original OxyContin® (OXY) (oxycodone HCl)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original OxyContin® (OXY) 80-mg tablet x 1 dose taken without food.
Study: NCT01612052
Drug: Antibiotic Prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparing the antibiotic treatment related to surgery
Study: NCT00123890
Drug: GW873140
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02038569
Drug: LEO 80185 gel
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00151203
Drug: Clarithromycin, Lenalidomide, Dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (Decadron®) will be given orally at a dose of 40 mg on days 1, 2, 3, 8, 15 and 22 during the first cycle and once a week on days 1, 8, 15, and 22 for each subsequent cycle.~Clarithromycin (Biaxin®) will be given orally at a dose of 500 mg twice a day beginning on day 2 of cycle 1.~Lenalidomide (Revlimid®) will be given orally at a dose of 25 mg daily beginning on day 3 and ending on day 21 of cycle 1 and on days 1-21 of subsequent cycles.
Study: NCT01205997
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ninety patients 20-60 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for femur surgery under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The magnesium group (groupM) received bupivacaine 15mg combined with 0.5ml magnesium 10%,The fentanyl group (group F) received bupivacaine 15mg combined with0.5 ml fentanyl\[25microgram\] and The placebo group (group P) received bupivacaine 15mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)
Study: NCT02346890
Drug: AZD1722
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01077375
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Placebo tablets, oral administration, twice daily for 10 weeks during randomized, double-blind treatment period. Duloxetine capsules, oral administration, 30 mg/day for 1 week after randomization to effect a duloxetine down-taper.~* Placebo tablets, twice daily for 1 week during double-blind down-taper treatment period.
Study: NCT03725436
Drug: MDM2/MDMX Inhibitor ALRN-6924
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT02793648
Drug: Ascorbic Acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two daily oral doses of 200mg of encapsulated vitamin C twice a day, administered at breakfast and dinner
Study: NCT02793648
Drug: PLACEBO
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two daily oral doses of 200mg of encapsulated placebo, administered at breakfast and dinner
Study: NCT02637284
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 1 a: Healthy volunteers will take a single dose of 1, 3 or 6 tablets by mouth of PCO-03 (placebo) as a control group.~Phase 1b: All subjects will take 3 tablets of PCO-03 (placebo) every 8 hours during two weeks, as a control group.
Study: NCT01064830
Drug: vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: apply 2 drops to 2 target fingernails under occlusion daily for 20 weeks
Study: NCT03720392
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: a harmless pill, medicine, or procedure prescribed more for the psychological benefit to the patient than for any physiological effect.
Study: NCT03725267
Drug: Melatonin Pill
Normalized name: melatonin Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 1 pill of melatonin each day during polymyxin B therapy for a maximum of 14 days.
Study: NCT03725267
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 1 pill of placebo each day during polymyxin B therapy for a maximum of 14 days.
Study: NCT02700087
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with symptomatic laryngomalacia who meet inclusion criteria will be randomized to receive placebo, ranitidine or famotidine, in order to see if these medications help their symptoms to resolve.
Study: NCT04581824
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed will be administered at 500 milligram per meter square (mg/m\^2 ) IV through a 10 minute IV infusion Q3W, up to a maximum of 35 cycles (each cycle of 21 days).~Cisplatin will be administered at 75 mg/m\^2 through a 30 minute IV infusion Q3W for 4 cycles (each cycle of 21 days) as per investigator decision.~Carboplatin will also be administered at area under the concentration time curve 5 milligram/milliliters/minute (mg/mL/min) (maximum dose: 750 mg) through a 15 to 60 minute IV infusion Q3W for 4 cycles (each cycle of 21 days) as per investigator decision.
Study: NCT01205997
Drug: placebo(distilled water)
Normalized name: petroleum distillate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ninety patients 20-60 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for femur surgery under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The magnesium group (groupM) received bupivacaine 15mg combined with 0.5ml magnesium 10%,The fentanyl group (group F) received bupivacaine 15mg combined with0.5 ml fentanyl\[25microgram\] and The placebo group (group P) received bupivacaine 15mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)
Study: NCT02560363
Drug: AZD9977 immediate release (IR) oral suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg (4.8 mL x 25 mg/mL) oral suspension, single dose
Study: NCT02560363
Drug: AZD9977 extended release (ER) capsules [fast]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg (2 x 60mg capsules) single dose
Study: NCT02560363
Drug: AZD9977 extended release (ER) capsules [intermediate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg (2 x 60mg capsules) single dose
Study: NCT02560363
Drug: AZD9977 extended release (ER) capsules [slow]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg (2 x 60mg capsules) single dose
Study: NCT02292966
Drug: DCV/ASV/BCV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each participant will each receive daclatasvir (30mg), asunaprevir (200mg) and beclabuvir (75mg) in a fixed-dose combination oral tablet for twice daily administration with food.
Study: NCT00593580
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02948101
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT02013453
Drug: 5FU
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered by infusion.
Study: NCT03201913
Drug: TTC-352
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 1 study to determine the maximum tolerated dose (MTD) of TTC-352.
Study: NCT03612856
Drug: AB023- Dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single dose of 0.25 mg/kg AB023.
Study: NCT03612856
Drug: AB023-Dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single dose of 0.5 mg/kg AB023.
Study: NCT03612856
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single dose of placebo.
Study: NCT01513200
Drug: Bendavia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendavia for infusion Constant intravenous infusion (Bendavia 0.25mg/kg/hr) for 4 hours
Study: NCT01606878
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01606878
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02780323
Drug: CELBESTA®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet of CELBESTA® and 1 tablet of CELEBREX® placebo, twice daily for 6 weeks
Study: NCT02780323
Drug: CELEBREX®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet of CELEBREX® and 1 tablet of CELBESTA® placebo, twice daily for 6 weeks
Study: NCT02780323
Drug: CELEBREX® placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet of CELBESTA® and 1 tablet of CELEBREX® placebo, twice daily for 6 weeks
Study: NCT02780323
Drug: CELBESTA® placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet of CELEBREX® and 1 tablet of CELBESTA® placebo, twice daily for 6 weeks
Study: NCT00586664
Drug: Bepreve (bepotastine besilate ophthalmic solution) 1.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: sterile ophthalmic solution
Study: NCT00586664
Drug: placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: sterile ophthalmic solution
Study: NCT04173793
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous injection
Study: NCT01439815
Drug: Saline Nasal Spray
Normalized name: Saline Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: two sprays in each nostril once daily
Study: NCT02069340
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT00591526
Drug: Arac
Normalized name: Carac
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ommit ARAC in the chemotherapy
Study: NCT00003673
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00861731
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: simvasatin therapy alone at the dose of 40 mg/day
Study: NCT00861731
Drug: EZE/simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: EZE/simvastatin combined therapy at the dose of 10/20 mg/day
Study: NCT00861731
Drug: EZE/simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: EZE/simvastatin combined therapy at the dose of 10/40 mg/day
Study: NCT02354352
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 26 Subjects will take Eplerenone, one 50mg capsule by mouth once daily for 12 months.
Study: NCT02354352
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 26 Subjects will take Spironolactone, one 50mg capsule by mouth once daily for 12 months.
Study: NCT04442178
Drug: CYT107
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM administration at 10μg/kg twice a week for three weeks and up to 7 administrations according to Hospital length of stay
Study: NCT04442178
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM administration at 10μg/kg twice a week for three weeks and up to 7 administrations according to Hospital length of stay
Study: NCT01496937
Drug: GLPG0974
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00791154
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is administered with Carboplatin and Etoposide
Study: NCT02232880
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will be treated with chlorthalidone 25 mg/day, lisinopril 20 mg/day \[Patients with a history of adverse reaction to lisinopril will be treated with losartan 50 mg/day\], amlodipine 5 mg/day and spironolactone 25 mg bid as standardized treatment of hypertension prior to randomization and throughout the active treatment phase.
Study: NCT03603405
Drug: ADV/HSV-tk (gene therapy)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigational adenovirus gene therapy injected at tumor site followed by valacyclovir, radiotherapy, and chemotherapy
Study: NCT00795483
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic Acid 5mg/year
Study: NCT00795483
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (5mg/2years)
Study: NCT02848443
Drug: Trifluridine/tipiracil hydrochloride (S 95005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablets containing 15mg of trifluridine and 7.065mg of tipiracil hydrochloride, or 20mg of trifluridine and 9.42mg of tipiracil hydrochloride, given orally at the dose of 25 or 30 or 35 mg/m2/dose, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.
Study: NCT00266864
Drug: Testosterone Transdermal System (Androderm 5 mg patch)
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone Transdermal System (Androderm 5 mg patch)
Study: NCT04616079
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching single dose of REGN6490
Study: NCT03739996
Drug: Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Normalized name: Non-nucleoside reverse transcriptase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRTIs will not be provided by the study. Participants will obtain NRTIs outside of the study through routine care.
Study: NCT02338336
Drug: Nowarta110
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nowarta110 contains fig extract as the main drug substance, and colloidal silver is used as a medium for penetration of fig extract into the wart lesion. Liquid for topical administration.
Study: NCT02338336
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo liquid for topic administration.
Study: NCT04057118
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration, twice per day
Study: NCT01302132
Drug: ASP1941
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution
Study: NCT00729222
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: rolofylline placebo IV infusion over 4 hours.
Study: NCT02850081
Drug: Statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care treatment (one of four):~* Simvastatin (to 40mg without amlodipine)~* Simvastatin (to 20 mg if currently on amlodipine)~* Atorvastatin (to 80mg)~* Rosuvastatin (to 20mg)
Study: NCT00627146
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 days